Newsletter | March 25, 2026

03.25.26 -- Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.

FEATURED ARTICLE

Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.

On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq.

INDUSTRY INSIGHTS

Integrating The Patient Pathway For Clinical Success

Explore how a unified workflow—integrating clinical fit validation with formal trial entry—minimizes friction and reduces the industry’s staggering 60–80% screen failure rates.

Advancing Trial Quality Through Early Health Equity Planning

See how early inclusion boosts trial enrollment, strengthens data quality, and drives better outcomes — especially in oncology and rare diseases.

If Sustainability Is A Priority, Why Is Progress So Slow?

Sustainability is now central to biopharma strategy. New data reveals why commitments aren’t translating into action, and the roadblocks leaders must address to turn environmental ambition into change.

Smart Manufacturing: A Strategic Imperative For Pharma's Future

Pharmaceutical manufacturing is evolving rapidly. Find out how digital technologies like AI, digital twins, and software-defined automation are driving smarter, more agile production.

Handle Single-Use Technology Biopharma Waste: Data Sharing, Collaboration

Learn more about data sharing and collaboration to enable a better environmental impact of single-use technologies (SUTs) and quantifying the single-use plastic waste generated when manufacturing mAbs.

Smarter Resource Allocation For Bio‑Pharma Efficiency

Build more agile, resilient operations by reducing waste and maximizing the value of current assets, enabling biopharma teams to capture meaningful savings and operate with greater efficiency.